As a professional organization established precisely to address this core challenge, EconCare Technology Pty Ltd specializes in providing comprehensive local agent services for overseas medical device manufacturers. We are committed to serving as your most solid "regulatory bridge" and "compliance firewall" in the Chinese market. We fully understand that our role is by no means a mere nominal presence; rather, we act as a strategic partner fully authorized to fulfill all statutory obligations on behalf of overseas enterprises throughout the entire product lifecycle—from registration application to post-market surveillance. Our mission is to ensure that your innovative products can be marketed safely, lawfully, and seamlessly in China, enabling globally advanced medical technologies to focus on serving patients without any compliance concerns.

Mission: Simplify Compliance, Enable Borderless Innovation

In the medical device industry, compliance and innovation are the two sides of a balance, neither dispensable. The regulatory landscape for medical devices is complex and stringent. From product R&D to market launch, enterprises must navigate numerous regulatory barriers: NMPA registration and approval, rollout of the UDI (Unique Device Identification) system, implementation of the Marketing Authorization Holder system, establishment of adverse event surveillance frameworks, and constraints on commissioned manufacturing norms. Every regulation functions like a precision gear to guarantee product safety and efficacy.

However, for overseas enterprises with advanced medical technologies, these regulations form an intricate labyrinth. Language barriers, cultural disparities, and rapid shifts in policy dynamics all create invisible obstacles stifling innovation. Our mission is to break down these barriers: translate intricate NMPA regulations into actionable, clear roadmaps for clients, so overseas cutting-edge medical technologies can focus entirely on serving patients without regulatory worries.

We firmly believe medical device innovation safeguards human life and health. A novel cardiac pacemaker, high-precision diagnostic imaging equipment, or breakthrough biomaterial can transform patients’ lives. Yet the brilliance of innovation ought not to be dimmed by cumbersome compliance procedures. Therefore, we strive to act as a bridge connecting regulations and innovation: decode complex regulatory requirements with expertise, streamline compliance workflows with technology, mitigate potential risks with experience, allowing enterprises to fully dedicate resources to technological R&D and patient care.

Whether navigating strict NMPA oversight of the import medical device agent system, meeting full-lifecycle traceability mandates under the UDI system, fulfilling end-to-end accountability stipulated by the Marketing Authorization Holder system, or satisfying real-time response requirements for adverse event monitoring—we consistently uphold the goal of “simplifying compliance,” enabling truly borderless innovation and bringing global medical technological breakthroughs to patients across China.

Values: Accountability, Professionalism, Transparency, Win-Win Collaboration

In the medical device sector, a field tied to human life and health, our values are far more than slogans—they are actionable principles embedded in everything we do. All our services and decisions are built upon these foundations, supporting clients’ innovation journeys within the bounds of compliance.

Accountability First: Compliance as the Bottom Line, Responsibility as the Lifeline

The unique nature of medical devices places immense weight on accountability. We fully recognize the legal significance of a Domestic Responsible Person: this role is not merely a regulatory requirement, but a solemn commitment to clients, patients and society. Pursuant to the Regulations on the Supervision and Administration of Medical Devices and relevant rules, domestic agents are obligated to assist overseas marketing authorization holders in fulfilling statutory duties, including registration applications, adverse event surveillance, post-market re-evaluation, and product recalls.

We treat our clients’ compliance risks as our own survival baseline: we courageously bear joint and several liability without evasion, and pursue zero-defect risk pre-control. For instance, we operate a 7×24-hour early warning mechanism for adverse event monitoring. Upon receiving a suspected incident report, we immediately launch joint investigations alongside overseas holders to ensure timely reporting and risk containment within statutory deadlines. For UDI implementation, we support clients one year in advance with code generation, label design and database submission, preventing customs clearance delays stemming from non-compliance. Accountability means rigorous standards for every process and unwavering delivery on every promise.

Professionalism as Our Foundation: Rooted in Regulations, Sharpened by Experience

Medical device compliance is a highly specialized discipline that integrates profound regulatory knowledge, real-world practice and technical capabilities. Our team consists of senior specialists with over a decade of experience in medical device regulation, including former NMPA reviewers, international registration experts, quality system consultants and technical document engineers. They possess in-depth mastery of regulatory frameworks across major global markets including NMPA, FDA and EU MDR, and full-cycle expertise in registration strategy formulation, clinical trial design, quality management system construction and technical dossier compilation.

We maintain a dynamically updated regulatory database and AI monitoring system to track policy revisions in real time—such as updates to the Catalogue of Medical Devices Prohibited from Commissioned Manufacturing, expansion of Marketing Authorization Holder pilot programs, and adjustments to UDI implementation timelines—ensuring accurate, forward-looking regulatory interpretation.

Professionalism extends beyond mastery of regulatory clauses; we deliver tailor-made solutions aligned with each enterprise’s actual conditions. For innovative medical devices, we guide clients to leverage fast-track channels to accelerate approval. For commissioned manufacturing scenarios, we advise enterprises on resource optimization under the Marketing Authorization Holder system while drawing clear boundaries of accountability.

Transparent Communication: Symmetric Information, Trust as the Link

The complexity of compliance work often leads to information asymmetry, triggering anxiety and latent risks. We adhere to transparent communication to keep clients fully updated on product status:

• Progress Synchronization: Real-time updates on registration progress, review comments and rectification requirements via exclusive systems, eliminating information gaps.

• Risk Early Warning: Timely delivery of analytical reports and response strategies for policy changes, official inquiries and potential non-compliance issues.

• Data Sharing: Regular visual reports covering adverse event surveillance data, market feedback and quality audit outcomes.

• Joint Decision-Making: Joint  evaluation of material compliance matters (such as label revisions or registration strategy adjustments) to reach consensus.

During an unannounced NMPA inspection for one client, we fully disclosed self-inspection findings in advance, co-developed rectification plans and accompanied the inspection throughout, ultimately securing a smooth pass. Transparency eliminates doubts, fosters deep trust and evolves cooperation into genuine partnership.

Win-Win Collaboration: Client Success Equals Our Success

We do not position ourselves as a mere service provider, but as an extended team for clients operating in the Chinese market. Successful medical device market launch marks only the starting point of the compliance journey. We provide full-lifecycle support spanning product registration and ongoing compliance (e.g., annual re-evaluation, license renewal), market access and risk control. We align our goals with clients’ commercial objectives: optimizing cost structures (e.g., reducing rejection risks through pre-submission material review), accelerating market responsiveness (e.g., expediting renewals via agency services), and boosting competitiveness (e.g., capturing policy dividends through regulatory intelligence alerts).

For example, a multinational medical device enterprise faced product detention risks amid UDI enforcement. We assembled a dedicated task force overnight, completing code scheme revisions and system integration within 48 hours to guarantee on-schedule customs clearance, avoiding millions of US dollars in losses. Win-win collaboration means shared commercial achievements, joint development of optimal solutions balancing compliance and innovation, and collective advancement of medical technology.

Upholding Our Values Amid Evolving Regulatory Frameworks

Compliance is a red line and the cornerstone of high-quality development within the medical device industry. In recent years, NMPA has continuously strengthened supervision, advancing the “Four Strictest Standards” (stringent standards, rigorous supervision, severe penalties and serious accountability), rolling out Marketing Authorization Holder pilot programs, and fully deploying the UDI system. The regulatory framework is increasingly aligned with international norms, with supervision intensity escalating steadily. This brings both challenges and opportunities, pushing enterprises to elevate quality management and speed up innovative iteration. Our mission and values are rooted in this evolving regulatory landscape:

• Accountability & Professionalism: Under the Marketing Authorization Holder system, holders bear full-lifecycle accountability, requiring agents to not only master regulations but also support clients in building quality management systems covering R&D, manufacturing, distribution and after-sales services.

• Transparency & Win-Win Collaboration: Refined adverse event surveillance systems mandate transparent information channels linking enterprises, regulators, medical institutions and patients to jointly safeguard product safety.

• Borderless Innovation: Digital regulatory tools including UDI and electronic registration certificates inherently lower compliance costs, boost efficiency and facilitate global technological exchange.

Moving forward, we will keep pace with regulatory evolution, anchored by accountability, steered by professionalism, connected via transparency, and forge win-win futures with clients across the medical device industry. Every compliant medical device will stand as a beacon protecting lives; every innovative breakthrough will cross borders to illuminate the future of human health.

Closing Remarks

Compliance is not a constraint, but a safeguard. Accountability is not a burden, but a conviction. Within this noble medical device sector, Yikangshengyuan will take our mission as a beacon and our values as a compass. Amid shifting regulatory tides, we will carve out a clear, secure and efficient compliance pathway for clients, enabling truly borderless innovation and reliable protection for patients.